[
    "ee Perry et al, 2008, Bioorg, Med. Chem. Lett. 1 8:4700-04; International Patent Application No. WO 08/001076), </p> Compound (XXIII) is also known as ethyl 2-morpholino-7-oxo-4,5,6,7- tetrahydrobenzo[b]thiophene-3-carboxylate. </p> Compound (XXIV) is also known as (S)-2-(3-((l H-indol-3- yl)methyl)morphoJino)-4-meihylthiazole-5-carboxaiTiide. </p> Compound (XXV) is also known as 2-(6-bromo-2H-benzo[b][ l ,4]oxazin- 4(3H)-yl)-5,5-dimethyl-5,6-dihydrobenzo[d]thiazol-7(4H)-one. </p> Compound (XXVI) is also known as (S)-methyl 3-((4-(6,6-dimethyl-4-oxo- 4,5,6,7-tetrahydiOthiazolo[5<sub>)</sub>4-c]pyndin-2-yl)morpholin-3-yl)methyt)- l -methyI-ltLindole-5- carboxylate. </p> Compounds (XXITI)-(XXVI) were reported as PT3K p i 10 delta inhibitors (International Patent Application Nos. WO 07/1 1504, WO 08/044022 and WO 08/047109). </p> Compound (XXVII) is also known as TGI OO- 1 15 or 3,3'-(2,4- diaminopteridine-6,7-diyl)diphenol. Compound (XXVII) was reported to have an P13K p i 10 delta ICJO of 0.235 \u03bc\u039c (see Palanki et al., 2007, J. Med. Chem. 50:4279). </p> Compound (XXVII1) is also known as TG100-713 or 3-(2,4-diaminopteridin- 6-yi)phenol. Compound (XXVIII) was reported to have an PI3 p i 10 delta IC<sub>50</sub> of 24 nM (see Palanki et al., 2007, J. Med, Chem, 50:4279; Doukas et al., 2006, Proc. Nat. Acad. Sci. 103: 19866-71 ). </p> Compound (XXIX) is also known as TG 100- 1 10 or 6-( l H-indol-4- yl)pteridine-2,4-diamine. Compound (XXIX) was reported to have an PI3 pi 10 delta IC50 \n\n of 0.064 \u03bc\u039c (see Palanki et al., 2007, J. Med. Chem. 50:4279; Doukas et at., 2006, Proc. Nat. Acad. Sci. 103: 19866-71). </p> Compound (XXX) or a pharmaceutically acceptable salt thereof may be prepared using methods known to those skilled in the organic chemistry art (see Knight et al., 2010, ACS Med. Chem. Lett. 1 :39-43 and references therein) or obtained from commercial sources. </p> In one embodiment, in Compound (XXX) R' is CH and R<sup>2</sup> is 2,2-(5- thiazo!idiiiyi-2<sub>(</sub>4-dione)- l -ethylenyl, and the compound useful within the methods of the invention is Compound (XXXI): </p><img id=\"imgf000028_0001\" path=\"imgf000028_0001.tif\" file=\"https://surechembl.org/api/assets/attachment/172147921/WO/20120119/A1/002012/00/94/52/imgf000028_0001.tif\"/></p>also known as (Z)-5-((4-(pyridin-4-yi)qiiinolin-6-yl)methylene)thiazolidine-2,4-dione, or a pharmaceutically acceptable salt thereof. </p> In another embodiment, in Compound (XXX) R<sup>l</sup> is N and R<sup>2</sup> is 2-methoxy-3- (2,4-difluoiObenzenosulfonyiamino)-pyridin-5-yl, and the compound useful within the methods of the invention is Compound (XXXII): </p><img id=\"imgf000028_0002\" path=\"imgf000028_0002.tif\" file=\"https://surechembl.org/api/assets/attachment/172147917/WO/20120119/A1/002012/00/94/52/imgf000028_0002.tif\"/>\n (XXXII), also known as 2<sub>}</sub>4-difliioro-N-(2-methoxy-5-(4-(pyridin-4-yi)qiiinolin-6-yl)pyridin-3-yl)- benzenesulfonamide, or a pharmaceutically acceptable salt thereof. Compou"
]